IVIG Shows No Impact on VTE Risk in Dermatomyositis Patients

The rate of venous thromboembolism did not increase in dermatomyositis patients treated with intravenous immunoglobulin, compared with those not treated with IVIG.
MDedge News

source https://www.medscape.com/viewarticle/991881?src=rss